RxDoctor Payments Data

Rosemary Bergeron Johnson, PA

Physician Assistant · Eastman, GANPI 1043255318

Payments from drug & device makers

$707in general payments, 2019–2025

Across 27 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$199
  • AbbVie$149
  • Abbott$108
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$67
  • E.r. Squibb & Sons, L.L.C.$60
  • Johnson & Johnson$45
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$65893%
  • Education$507%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$707 in reported general payments places this provider in the 60th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$4,067
Medicare patients
33
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate91$319,635
Invega TrinzaPaliperidone Palmitate17$152,537
Austedo XrDeutetrabenazine22$107,747
VraylarCariprazine Hcl47$69,048
Paliperidone ErPaliperidone55$7,794
Olanzapine340$6,453
Oxcarbazepine115$4,274
Ziprasidone Hcl63$3,866
Hydroxyzine Pamoate179$2,695
Duloxetine Hcl206$2,528
Divalproex Sodium150$2,448
Venlafaxine Hcl ErVenlafaxine Hcl209$2,331
Quetiapine Fumarate190$1,997
Buspirone Hcl104$1,540
Gabapentin131$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$45$472,172108 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$199$107,74722 claims
AbbVieVraylar$149$69,04847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Eastman

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →